Receptor-interacting serine/threonine-protein kinase 3 (RIPK3) is the essential downstream executor of necroptosis, a regulated form of programmed necrotic cell death. Unlike its upstream partner RIPK1, RIPK3 functions primarily as a kinase that executes the necroptotic death program by phosphorylating and activating MLKL [1]. The formation of the RIPK1-RIPK3 necrosome creates an amyloid-like signaling platform that drives the necrotic cell death cascade implicated in multiple neurodegenerative diseases.
RIPK3 is increasingly recognized as a critical mediator of neuronal death in Alzheimer's disease, Parkinson's disease, ALS, and other neurological conditions. Unlike RIPK1, which has been successfully targeted in clinical trials with kinase inhibitors like GSK2982772, RIPK3 inhibitors remain in preclinical development despite strong mechanistic rationale for neuroprotection.
RIPK3 is a 517-amino acid serine/threonine protein kinase with a molecular weight of 56.8 kDa. Its domain architecture includes:
The N-terminal kinase domain contains the canonical serine/threonine kinase fold with:
The kinase domain is responsible for:
The RIP Homotypic Interaction Motif (RHIM) mediates:
The RHIM domain contains:
The C-terminal region:
| Feature | RIPK1 | RIPK3 |
|---|---|---|
| Kinase domain | Catalytically active | More potent kinase activity |
| RHIM domain | Present | Present, forms stronger amyloid |
| Death domain | Present (C-terminus) | Absent |
| Necrosome role | Initiator | Executor |
| Kinase inhibitors | Multiple in development | Fewer selective compounds |
RIPK3 is the central executor of necroptosis, functioning through a well-characterized signaling cascade:
Step 1 — Necrosome Formation
Upon activation of TNFR1 or other death receptors, RIPK1 is recruited to the signaling complex. If ubiquitination fails or necrostatin-1 is absent, RIPK1 recruits RIPK3 through RHIM-RHIM interactions. This forms the necrosome — a higher-order amyloid signaling platform [2:1].
Step 2 — RIPK3 Activation
Within the necrosome:
Step 3 — MLKL Recruitment and Phosphorylation
Activated RIPK3 binds and phosphorylates MLKL:
Step 4 — Membrane Disruption
Phosphorylated MLKL forms oligomers that:
Beyond necroptosis, RIPK3 participates in several non-necroptotic pathways:
NF-κB Activation
RIPK3 can activate NF-κB independently of necroptosis [3], promoting inflammatory gene expression. This may contribute to chronic neuroinflammation in neurodegenerative diseases.
Inflammasome Regulation
RIPK3 interacts with the NLRP3 inflammasome and may prime or activate inflammasome signaling, linking necroptosis to interleukin-1β production.
Metabolic Regulation
RIPK3 influences mTOR signaling and cellular metabolism, with implications for neuronal energy homeostasis.
In non-diseased states, RIPK3:
The relatively restricted expression of RIPK3 in the CNS under normal conditions suggests that necroptosis is not a major pathway in healthy neurons, but becomes activated in disease contexts.
RIPK3-mediated necroptosis has emerged as a significant contributor to neuronal death across multiple neurodegenerative diseases. The restricted expression of RIPK3 in the healthy brain becomes elevated in disease states, making it an attractive therapeutic target.
RIPK3 activation in Alzheimer's disease contributes to pathology through multiple mechanisms:
Elevated Expression
Pathological Co-localization
Neuronal Death Mechanisms
Evidence from Models
In Parkinson's disease, RIPK3-mediated necroptosis contributes to dopaminergic neuron loss:
Dopaminergic Neuron Vulnerability
Pathogenic Triggers
Neuroprotection
RIPK3 plays a critical role in ALS pathogenesis:
Motor Neuron Death
Pathogenic Mechanisms
Therapeutic Potential
RIPK3 contributes to Huntington's disease pathology:
RIPK3-mediated necroptosis of oligodendrocytes:
In acute CNS injury:
Several RIPK3 inhibitors have been developed but none have reached clinical trials:
GSK'872 (GSK2399872A)
HS1371
Zabaditer
Compound 3z
Kinase-Independent Functions
Selectivity Challenges
Expression Patterns
BBB Penetration
Given the interconnected nature of cell death pathways, combination approaches may be superior:
RIPK1 + RIPK3 Inhibition
RIPK1 + Caspase Inhibition
RIPK3 + Anti-inflammatory
Unlike RIPK1 inhibitors (GSK2982772 completed Phase I), no RIPK3 inhibitors have reached clinical trials for any indication. The development has focused on:
This represents both a gap and an opportunity for RIPK3-targeted neuroprotective therapies.
| Interactor | Relationship | Disease Relevance |
|---|---|---|
| RIPK1 | Necrosome partner | Initiation and scaffolding |
| MLKL | Phosphorylation substrate | Executioner of necroptosis |
| DAI/ZBP1 | RHIM-containing sensor | Viral infection response |
| TRIF | TLR3/4 adaptor | Pathogen recognition |
| PGAM5 | Mitochondrial phosphatase | ROS generation |
| Drp1 | Mitochondrial fission | Mitochondrial dysfunction |
| TAK1 | Kinase interaction | NF-κB activation |
| FADD | Apoptosis adaptor | Cross-talk with apoptosis |
| Caspase-8 | Protease | Apoptosis/necroptosis choice |
Under physiological conditions, RIPK3 expression in the CNS is relatively low:
In neurodegenerative diseases, RIPK3 expression dramatically increases:
This disease-specific upregulation makes RIPK3 an attractive target — inhibiting it should have limited effects on normal physiology while providing significant neuroprotection in disease.
RIPK3 activity can be monitored through:
Phospho-RIPK3 (Thr182)
Necrosome Formation
Phospho-MLKL (Thr357)
These biomarkers could be useful for patient selection and response monitoring in clinical trials.
Knockout Mice
Transgenic Models
Inhibitors
Sun L et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell. 2012;148(1-2):213-227. https://doi.org/10.1016/j.cell.2012.01.007. 2012. ↩︎
Li J et al. The RIP1/RIP3 necrosome forms a functional amyloid signaling complex required for programmed necrosis. Cell. 2012;150(2):339-350. https://doi.org/10.1016/j.cell.2012.06.019. 2012. ↩︎ ↩︎
Dannappel M et al. RIPK3 maintains tumor-initiating cell function in diffuse large B-cell lymphoma via NF-κB. J Exp Med. 2021;218(8):e20210474. https://doi.org/10.1084/jem.20210474. 2021. ↩︎
Caccamo A et al. Necroptosis drives Alzheimer's disease pathology in vivo. J Neurosci. 2017;37(47):9254-9269. https://doi.org/10.1523/JNEUROSCI.1867-17.2017. 2017. ↩︎
Hu Y et al. RIPK3 deficiency blocks neuronal death in Parkinson's disease models. Cell Death Dis. 2020;11(8):664. https://doi.org/10.1038/s41419-020-2597-7. 2020. ↩︎
Re DB et al. Necroptosis drives motor neuron death in models of both sporadic and familial ALS. Neuron. 2014;81(5):1001-1018. https://doi.org/10.1016/j.neuron.2014.01.011. 2014. ↩︎
Momoi M et al. Therapeutic potential of necroptosis inhibition in Huntington's disease. Brain Res Bull. 2019;149:77-84. https://doi.org/10.1016/j.brainresbull.2019.03.019. 2019. ↩︎
Meng Y et al. RIPK3 mediates chronic neurodegeneration in traumatic brain injury. Neurotherapeutics. 2021;18(3):1735-1751. https://doi.org/10.1007/s13311-021-01040-5. 2021. ↩︎